Amgen Inc.

Surrozen Operating, Inc.

Wen-Chen Yeh

Zhihua Ma

Gayathri Swaminath

Yinhong Chen

Aarif Yusuf Khakoo

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Julie Anne Heath

Su-Jen Lai

Nobuko Nishimura

David John Kopecky

Yang Li

Ning Chen

Xiaoqi Chen

Zice Fu

Xiaodong Wang

Jeffrey Thomas Mihalic

Alan C Cheng

Richard V Connors

Mikkel V Debenedetto

Steven H Olson

Julio Cesar Medina

Frank Kayser

Xiaohui Du

Matthew R Kaller

Daniel B Horne

Jeffrey Deignan

James S Harvey

Kevin Chao Yang

Ted Charles Judd

Simon J Hedley

Tom Zhiye Yuan

Lawrence R McGee

Robert P Farrell

Randall J Brezski

Claudia Yvonne Janda

Zhengjian Zhang

Chenggang Lu

Lars V Heumann

YuMei Xiong

Malgorzata Wanska

Kuo-Pao Lai

Philip Dean Ramsden

Tristan William Fowler

Parthasarathy Sampathkumar

Matthew Irvine Brown

Bei Shan

Jackie Zeqi Sheng

Charles Kreiman

Shengjiang Tu

Leonard Presta

Ankit Sharma

Liqin Xie

Hui Chen

Thomas Lopez

Alykhan S Motani

Jennifer Jean Brady

Teppei Yamaguchi

Jiangwen Majeti

Sujen Lai

Matthew Brown

Yumei Xiong

The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.

Tissue-specific WNT signal enhancing molecules and uses

The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Wnt surrogate molecules and uses thereof

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

Liver-specific Wnt signal enhancing molecules and uses thereof

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Anti-frizzled antibodies and methods of use

The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.

Tissue-specific Wnt signal enhancing molecules and uses thereof

WNT surrogate molecules and uses thereof

The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.

Anti-LRP5/6 antibodies and methods of use

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Alkyl substituted triazole compounds as agonists of the APJ Receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Triazole phenyl compounds as agonists of the APJ receptor

Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Growing community of inventors

Belmont, CA, United States of America

Wen-Chen Yeh